The deal, financial terms of which were not disclosed, will see Mississauga, Canada-based Alphora two facilities join Eurofins’ network of drug testing laboratories.
Alphora focuses on the production and testing of active pharmaceutical ingredients (APIs), including those made using multi-step syntheses, cytotoxics and highly potent ingredients. The firm employs 100 people.
According to its website, Alphora expects to generate revenue of C$30m ($22.6) in 2017.
Eurofins described the deal as its entry into what it calls the contract research, development and manufacturing organization (CRDMO) market.
CEO Gilles Martin said: “We are pleased to welcome Alphora to the Eurofins Group. Alphora’s competencies and footprint further strengthen Eurofins’ global leadership in the rapidly-growing biopharmaceutical testing market.”
Eurofins declined to comment further.
Testing capacity
The addition of Alphora’s testing capabilities is in keeping with Eurofins’ expansion of its biopharmaceutical testing services capacity.
Last August Eurofins said it was adding 4,400m2 of lab space at its bioanalytical facility in Dungarvan, Ireland and committed to a further 1,800m2 at a second site nearby.
In March this year it said it will spend £4m ($5m) on a facility in Livingston, Scotland.